Niba Healthcare Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Niba Healthcare Pharmaceutical Export Portfolio Dataset — 3 Products, $86.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Niba Healthcare — Pharmaceutical Exporter Profile (2026) | 3 Products, $86.5K Trade | TransData Nexus

Product Portfolio — Top 3 by Export Value

Niba Healthcare exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Niacin	Lipid & Metabolism	$55.5K	22	1.5%	7
2	Dapsone	Antimalarial & Antiparasitic	$23.8K	34	0.1%	11
3	Adalimumab	Biologics & Immunotherapy	$7.2K	9	0.6%	10

Niba Healthcare exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $86.5K. The top category is Lipid & Metabolism (64.1% of portfolio), followed by Antimalarial & Antiparasitic (27.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Niba Healthcare — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Niba Healthcare, established in 2018, is a sole proprietorship based in Nagpur, Maharashtra, India. The company specializes in manufacturing, exporting, and trading a diverse range of pharmaceutical products, including tablets, capsules, syrups, and injections. Under the leadership of Mr. Nishant Barethiya, Niba Healthcare has developed a reputation for delivering high-quality pharmaceutical formulations.

The company operates with an annual turnover ranging between ₹5 to ₹25 crore and employs a team of 11 to 25 individuals. Niba Healthcare is registered under the Goods and Services Tax (GST) with the number 27BFAPB0168Q1ZD and holds an Import Export Code (IEC) of BFAPB0168Q.

2Manufacturing Facilities

Niba Healthcare's manufacturing facility is located in Nagpur, Maharashtra. The plant is equipped to produce a variety of pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities and specializations are not publicly disclosed, the facility adheres to stringent quality standards, as evidenced by its ISO 9001:2015 certification.

3Key Leadership

Mr. Nishant Barethiya serves as the Proprietor of Niba Healthcare. His leadership has been instrumental in the company's growth and its commitment to delivering quality pharmaceutical products. Under his guidance, Niba Healthcare has established itself as a reliable exporter in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Niba Healthcare Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Niba Healthcare has made significant strides in exporting its pharmaceutical products to various international markets, including Korea, Saudi Arabia, the United Kingdom, Tanzania, and Kenya. The company's adherence to global quality standards, such as ISO 9001:2015 and WHO-GMP certifications, facilitates its entry into these regulated markets. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available.

2Emerging Markets

Niba Healthcare's export activities extend to regions in Africa, Latin America, and Southeast Asia, with notable shipments to countries like Tanzania and Kenya. The company's WHO-GMP certification enhances its credibility and facilitates access to these emerging markets. However, specific details regarding WHO prequalification and its impact on market access are not publicly disclosed.

3Geographic Strategy

Niba Healthcare's export strategy demonstrates a focus on both established and emerging markets, with shipments to regions such as Korea, Saudi Arabia, the United Kingdom, Tanzania, and Kenya. This diversified approach helps mitigate concentration risk and positions the company to leverage growth opportunities across different geographies. The strategic direction appears to be geared towards expanding its global footprint while maintaining a strong presence in key markets.

Niba Healthcare — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Niba Healthcare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export activities to various international markets suggest compliance with global regulatory standards, but detailed FDA-related information is not disclosed.

2WHO & EU GMP

Niba Healthcare holds WHO-GMP certification, indicating adherence to the World Health Organization's Good Manufacturing Practices. This certification underscores the company's commitment to maintaining high-quality manufacturing standards. However, specific details regarding EU GMP certificates and EDQM status are not publicly available.

3CDSCO & Indian Regulatory

Niba Healthcare operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds the necessary manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) are not publicly disclosed.

Niba Healthcare — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Niba Healthcare operates in a competitive pharmaceutical export market, with key competitors in overlapping categories such as lipid & metabolism, antimalarial & antiparasitic, and biologics & immunotherapy. While specific market share comparisons are not publicly available, Niba Healthcare's focus on high-quality formulations and adherence to international standards position it as a competitive player in these therapeutic areas.

2Key Differentiators

Niba Healthcare's commitment to quality is demonstrated through its ISO 9001:2015 and WHO-GMP certifications. The company's diverse product portfolio, including pharmaceutical injections, anticancer medicines, and anti-HIV drugs, caters to a wide range of therapeutic needs. Additionally, Niba Healthcare's strategic export activities to various international markets highlight its global reach and adaptability.

3Strategic Position

Niba Healthcare's current strategic direction focuses on manufacturing and exporting finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's adherence to international quality standards and its diverse product portfolio position it well for future growth in both established and emerging markets. While specific plans regarding generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services are not publicly disclosed, Niba Healthcare's commitment to quality and regulatory compliance suggests a strong foundation for strategic expansion.

Buyer Due Diligence Brief — Evaluating Niba Healthcare as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Niba Healthcare has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $86,000 USD across 65 shipments. The company's adherence to quality standards, as evidenced by its ISO 9001:2015 and WHO-GMP certifications, indicates a reliable manufacturing process. The diverse product portfolio and strategic export activities suggest a commitment to meeting global pharmaceutical demands.

2Certifications to Verify

Importers should verify the following certifications when considering Niba Healthcare as a supplier:

FDA Registration: Confirm the company's FDA facility registration status to ensure compliance with U.S. regulatory standards.

WHO-GMP Certification: Verify the WHO-GMP certification to ensure adherence to international manufacturing practices.

EU GMP Certification: Check for EU GMP certification to confirm compliance with European manufacturing standards.

Frequently Asked Questions — Niba Healthcare

How many pharmaceutical products does Niba Healthcare export from India?

Niba Healthcare exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Niacin ($55.5K), Dapsone ($23.8K), Adalimumab ($7.2K). Total export value is $86.5K.

What is Niba Healthcare's total pharmaceutical export value?

Niba Healthcare's total pharmaceutical export value is $86.5K, based on 65 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Niba Healthcare cover?

Niba Healthcare exports across 3 therapeutic categories. The largest are Lipid & Metabolism (64.1%, 1 products), Antimalarial & Antiparasitic (27.6%, 1 products), Biologics & Immunotherapy (8.3%, 1 products).

Get Full Niba Healthcare Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Niba Healthcare

Niba Healthcare — Export Portfolio & Destination Treemap

Who is Niba Healthcare? — Company Overview & Market Position

What Does Niba Healthcare Export? — Product Portfolio Analysis

Top Products by Export Value

Niba Healthcare Therapeutic Categories — 3 Specializations